This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahata, M.
Right arrow Articles by Narita, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahata, M.
Right arrow Articles by Narita, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 312-315, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.312-315.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro and In Vivo Efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae

Masahiro Takahata,* Masako Shimakura, Ritsuko Hori, Kazuo Kizawa, Yozo Todo, Shinzaburo Minami, Yasuo Watanabe, and Hirokazu Narita

Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan

Received 20 March 2000/Returned for modification 15 July 2000/Accepted 12 October 2000

T-3811, the free base of T-3811ME (BMS-284756), a new des-F(6)-quinolone, showed a potent in vitro activity (MIC at which 90% of the isolates tested are inhibited [MIC90], 0.0313 µg/ml) against Mycoplasma pneumoniae. The MIC90 of T-3811 was 4-fold higher than that of clarithromycin but was 4- to 8-fold lower than those of trovafloxacin, gatifloxacin, gemifloxacin, and moxifloxacin and was 16- to 32-fold lower than those of levofloxacin, ciprofloxacin, and minocycline. In an experimental M. pneumoniae pneumonia model in hamsters, after the administration of T-3811ME (20 mg/kg of body weight as T-3811, once daily, orally) for 5 days, the reduction of viable cells of M. pneumoniae in bronchoalveolar lavage fluid was greater than those of trovafloxacin, levofloxacin, and clarithromycin (20 and 40 mg/kg, orally) (P < 0.05).

* Corresponding author. Mailing address: Research Laboratories, Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama 930-8508, Japan. Phone: 81-76-431-8268. Fax: 81-76-431-8208. E-mail: MASAHIRO_TAKAHATA{at}toyama-chemical.co.jp.

Antimicrobial Agents and Chemotherapy, January 2001, p. 312-315, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.312-315.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Griffith, M. E., Moon, J. E., Johnson, E. N., Clark, K. P., Hawley, J. S., Hospenthal, D. R., Murray, C. K. (2007). Efficacy of Fluoroquinolones against Leptospira interrogans in a Hamster Model. Antimicrob. Agents Chemother. 51: 2615-2617 [Abstract] [Full Text]  
  • Fonseca-Aten, M., Salvatore, C. M., Mejias, A., Rios, A. M., Chavez-Bueno, S., Katz, K., Gomez, A. M., McCracken, G. H. Jr, Hardy, R. D. (2005). Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother. 49: 4128-4136 [Abstract] [Full Text]  
  • Morozumi, M., Hasegawa, K., Kobayashi, R., Inoue, N., Iwata, S., Kuroki, H., Kawamura, N., Nakayama, E., Tajima, T., Shimizu, K., Ubukata, K. (2005). Emergence of Macrolide-Resistant Mycoplasma pneumoniae with a 23S rRNA Gene Mutation. Antimicrob. Agents Chemother. 49: 2302-2306 [Abstract] [Full Text]  
  • Yoo, B. K, Triller, D. M, Yong, C.-S., Lodise, T. P (2004). Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections. The Annals of Pharmacotherapy 38: 1226-1235 [Abstract] [Full Text]  
  • Gajjar, D. A., Bello, A., Ge, Z., Christopher, L., Grasela, D. M. (2003). Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects. Antimicrob. Agents Chemother. 47: 2256-2263 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Bing, X., Duffy, L. B. (2003). In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 47: 161-165 [Abstract] [Full Text]  
  • Donati, M., Pollini, G. M., Sparacino, M., Fortugno, M. T., Laghi, E., Cevenini, R. (2002). Comparative in vitro activity of garenoxacin against Chlamydia spp.. J Antimicrob Chemother 50: 407-410 [Abstract] [Full Text]  
  • Malay, S., Roblin, P. M., Reznik, T., Kutlin, A., Hammerschlag, M. R. (2002). In Vitro Activities of BMS-284756 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 46: 517-518 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»